Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Cancer of the urinary bladder - cancer stat facts. SEER. Available at: https://seer.cancer.gov/statfacts/html/urinb.html.
   Google Scholar
• American Cancer Society. Key statistics for bladder cancer. Available at: https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html.
   Google Scholar
• Martin JW, Carballido EM, Ahmed A, et al. Squamous cell carcinoma of the urinary bladder: systematic review of clinical characteristics and therapeutic approaches. Arab J Urol. 2016;14(3):183–191. doi:10.1016/j.aju.2016.07.001
   PubMed Web of Science ®Google Scholar
• NCCN. NCCN clinical practice guidelines in oncology. Bladder Cancer. NCCN Evidence BlocksTM version 6. 2020. July 22, 2020:1–121.
   Google Scholar
• Mbeutcha A, Lucca I, Mathieu R, Lotan Y, Shariat SF. Current status of urinary biomarkers for detection and surveillance of bladder cancer. Urol Clin North Am. 2016;43(1):47–62. doi:10.1016/j.ucl.2015.08.005
   PubMed Web of Science ®Google Scholar
• Flaig TW, Spiess PE, Agarwal N, et al. Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology. JNCCN. 2020;18(3):329–354.
   Google Scholar
• FDA. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims; 2009.
   Google Scholar
• Siracusano S, Silvestri T, Bassi S, et al. Health-related quality of life after BCG or MMC induction for non-muscle invasive bladder cancer. Can J Urol. 2018;25(5):9480–9485.
   Web of Science ®Google Scholar
• Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus calmette-guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized southwest oncology group study. J Urology. 2000;163(4):1124–1129. doi:10.1016/S0022-5347(05)67707-5
   PubMed Web of Science ®Google Scholar
• Brausi M, Oddens J, Sylvester R, et al. Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014;65(1):69–76.
   PubMed Web of Science ®Google Scholar
• Skolarus TA, Ye Z, Zhang S, Hollenbeck BK. Regional differences in early stage bladder cancer care and outcomes. Urology. 2010;76(2):391–396. doi:10.1016/j.urology.2009.12.079
   Web of Science ®Google Scholar
• Strope SA, Ye Z, Hollingsworth JM, Hollenbeck BK. Patterns of care for early stage bladder cancer. Cancer. 2010;116(11):2604–2611. doi:10.1002/cncr.25007
   Web of Science ®Google Scholar
• Ades AE, Caldwell DM, Reken S, Welton NJ, Sutton AJ, Dias S. NICE DSU Technical Support Document 7: Evidence Synthesis of Treatment Efficacy in Decision Making: A Reviewer’s Checklist. National Institute for Health and Clinical Excellence; 2012.
   Google Scholar
• Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (Updated July 2019). 2019.
   Google Scholar
• Centre for Reviews and Dissemination, ed. CRD’s Guidance for Undertaking Reviews in Health Care. 3rd. CRD: University of York; 2009.
   Google Scholar
• Clark M, Harris NI, Martin S, et al. The impact of non-muscle invasive bladder cancer: qualitative research with patients. Value Health. 2015;18(7):A471. doi:10.1016/j.jval.2015.09.1248
   Web of Science ®Google Scholar
• Danielsson G, Malmstrom P-U, Jahnson S, Wijkstrom H, Nyberg T, Thulin H. Bladder health in patients treated with BCG instillations for T1G2-G3 bladder cancer-a follow-up five years after the start of treatment. Scand J Urol. 2018;52(5–6):377–384.
   PubMed Web of Science ®Google Scholar
• Dobbs R, Petros J, Usama A-Q, Ritenour C, Issa M, Canter D. Lower urinary tract symptoms (LUTS) as a presenting symptom for bladder cancer in a veteran population. J Urol. 2013;189(4SUPPL. 1):e525. doi:10.1016/j.juro.2013.02.2637
   Web of Science ®Google Scholar
• Fallah F, Fallah M, Sajadi Nia R. Thiotepa versus bacille calmette-guerin in non-muscle invasive bladder cancer. Curr Urol. 2012;6(3):160–164. doi:10.1159/000343532
   Google Scholar
• Hakim L, Djatisoesanto W, Soebadi M, et al. Clinical characteristics of bladder cancer in indonesia: the largest data presentation from five hospitals. Urology. 2012;80(3):S206–S207.
   Web of Science ®Google Scholar
• Minana B, Cozar JM, Palou J, et al. Bladder cancer in Spain 2011: population based study. J Urol. 2014;191(2):323–328. doi:10.1016/j.juro.2013.08.049
   PubMed Web of Science ®Google Scholar
• Mogensen K, Christensen KB, Vrang M-L, Hermann GG. Hospitalization for transurethral bladder resection reduces quality of life in Danish patients with non-muscle-invasive bladder tumour. Scand J Urol. 2016;50(3):170–174. doi:10.3109/21681805.2015.1132762
   PubMed Web of Science ®Google Scholar
• Dobbs RW, Hugar LA, Revenig LM, et al. Incidence and clinical characteristics of lower urinary tract symptoms as a presenting symptom for patients with newly diagnosed bladder cancer. Int Braz J Urol. 2014;40(2):198–203. doi:10.1590/S1677-5538.IBJU.2014.02.09
   Web of Science ®Google Scholar
• Gontero P, Oderda M, Mehnert A, et al. The impact of intravesical gemcitabine and 1/3 dose bacillus calmette-guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase ii trial. J Urol. 2013;190(3):857–862. doi:10.1016/j.juro.2013.03.097
   PubMed Web of Science ®Google Scholar
• Mostafid H, Cresswell J, Griffiths L, et al. Results of CALIBER: A phase II randomised feasibility trial of chemoablation with MMC versus surgical management in low risk non-muscle invasive bladder cancer (NMIBC). Br J Cancer. 2018;119(1):39.
   Google Scholar
• Koga H, Ozono S, Tsushima T, et al. Maintenance intravesical bacillus calmette-guérin instillation for ta, t1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG tokyo strain study group: maintenance intravesical BCG. International J Urology. 2010;17(9):759–766. doi:10.1111/j.1442-2042.2010.02584.x
   Web of Science ®Google Scholar
• Yokomizo A, Kanimoto Y, Okamura T, et al. Randomized controlled study of the efficacy, safety and quality of life with low dose bacillus calmette-guerin instillation therapy for nonmuscle invasive bladder cancer. J Urol. 2016;195(1):41–46. doi:10.1016/j.juro.2015.08.075
   Web of Science ®Google Scholar
• Zhang Z, Cao Z, Xu C, et al. Solifenacin is able to improve the irritative symptoms after transurethral resection of bladder tumors. Urology. 2014;84(1):117–121. doi:10.1016/j.urology.2014.02.034
   PubMed Web of Science ®Google Scholar
• Michielsen D, Coomans D. Intravesical chemotherapy or immunotherapy for intermediate-risk non-muscle invasive bladder cancer: does the patient mention a different quality of life? Urology. 2013;82(3SUPPL. 1):S130–S131.
   Google Scholar
• Yoshio S, Yoshimura K, Matsui Y, et al. Assessment of lower urinary tract symptoms after bacille calmette-guerin instillation therapy for non-muscle-invasive bladder cancer. Urology. 2012;80(3SUPPL. 1):S221.
   Google Scholar
• Schmidt S, Riel R, Frances A, et al. Bladder cancer index: cross-cultural adaptation into Spanish and psychometric evaluation. Health Qual Life Outcomes. 2014;12(1):20. doi:10.1186/1477-7525-12-20
   Web of Science ®Google Scholar
• Park J, Shin DW, Kim T-H, et al. Development and validation of the korean version of the european organization for research and treatment of cancer quality of life questionnaire for patients with non-muscle invasive bladder cancer: EORTC QLQ-NMIBC24. Cancer Res Treat. 2018;50(1):40–49. doi:10.4143/crt.2016.594
   Web of Science ®Google Scholar
• Sapre N, Wooten A, Siddons H, et al. Tumour recurrence and intravesical BCG significantly impact upon health related quality of life in patients undergoing conservative management for superficial bladder cancer. Eur Urol Suppl. 2013;12(1):e704. doi:10.1016/S1569-9056(13)61186-0
   Google Scholar
• Wei L, Li Q, Liang H, Jianbo L. The quality of life in patients during intravesical treatment and correlation with local symptoms. J Chemotherapy. 2014;26(3):165–168. doi:10.1179/1973947813Y.0000000126
   PubMed Web of Science ®Google Scholar
• Schmidt S, Frances A, Lorente Garin JA, et al. Quality of life in patients with non-muscle-invasive bladder cancer: one-year results of a multicentre prospective cohort study. Urol Oncol. 2015;33(1):19.e7–19.e15. doi:10.1016/j.urolonc.2014.09.012
   Web of Science ®Google Scholar
• Krajewski W, Halska U, Poletajew S, et al. Influence of transurethral resection of bladder cancer on sexual function, anxiety, and depression. Adv Exp Med Biol. 2018;1116(0121103, 2lu):37–50.
   Web of Science ®Google Scholar
• Steinberg RL, Thomas LJ, Mott SL, O’donnell MA. Multi-perspective tolerance evaluation of bacillus calmette-guerin with interferon in the treatment of non-muscle invasive bladder cancer. Bladder Cancer. 2019;5(1):39–49. doi:10.3233/BLC-180203
   Web of Science ®Google Scholar
• Singer S, Ziegler C, Schwalenberg T, Hinz A, Gotze H, Schulte T. Quality of life in patients with muscle invasive and non-muscle invasive bladder cancer. Support Care Cancer. 2013;21(5):1383–1393. doi:10.1007/s00520-012-1680-8
   PubMed Web of Science ®Google Scholar
• Ho B, Kan C, To H, et al. Health related quality of life after one-year maintenance intravesical Bacillus Calmette-Guerin for non-muscle invasive bladder: experience from a urology centre in Hong Kong. BJU Int. 2012;111(4–5):5.
   Google Scholar
• Chung J, Kulkarni GS, Morash R, et al. Assessment of quality of life, information, and supportive care needs in patients with muscle and non-muscle invasive bladder cancer across the illness trajectory. Supportive Care Cancer. 2019;27(10):3877–3885. doi:10.1007/s00520-019-4649-z
   Web of Science ®Google Scholar
• Fung C, Pandya C, Guancial E, et al. Impact of bladder cancer on health related quality of life in 1,476 older Americans: a cross-sectional study. J Urology. 2014;192(3):690–695. doi:10.1016/j.juro.2014.03.098
   Web of Science ®Google Scholar
• Brisbane WG, Holt SK, Winters BR, et al. Nonmuscle invasive bladder cancer influences physical health related quality of life and urinary incontinence. Urology. 2019;125:146–153. doi:10.1016/j.urology.2018.11.038
   Web of Science ®Google Scholar
• Smith AB, Jaeger B, Pinheiro LC, et al. Impact of bladder cancer on health-related quality of life. BJU Int. 2018;121(4):549–557. doi:10.1111/bju.14047
   PubMed Web of Science ®Google Scholar
• Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41(5):582–592. doi:10.1097/01.MLR.0000062554.74615.4C
   PubMed Web of Science ®Google Scholar
• Martinez-Pineiro L, Portillo JA, Fernandez JM, et al. Maintenance therapy with 3-monthly bacillus calmette-guerin for 3 years is not superior to standard induction therapy in high-risk non-muscle-invasive urothelial bladder carcinoma: final results of randomised cueto study 98013. Eur Urol. 2015;68(2):256–262. doi:10.1016/j.eururo.2015.02.040
   Web of Science ®Google Scholar
• Tan WS, Panchal A, Buckley L, et al. Radiofrequency-induced thermo-chemotherapy effect versus a second course of bacillus calmette-guerin or institutional standard in patients with recurrence of non-muscle-invasive bladder cancer following induction or maintenance bacillus calmette-guerin therapy (hymn): a phase iii, open-label, randomised controlled trial. Eur Urol. 2019;75(1):63–71.
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Perdona S, Damiano R, et al. Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer. 2010;116(8):1893–1900.
   PubMed Web of Science ®Google Scholar
• Mondal HP, Yirang K, Mukhopadhyay C, Adhikary SS, Dutta B, Bhoj SS. Prospective randomized study between intravesical BCG and mitomycin-C for non-muscle-invasive urothelial carcinoma of urinary-bladder post TURBT. Bangladesh J Med Sci. 2016;15(1):74–77. doi:10.3329/bjms.v15i1.19161
   Google Scholar
• Miyazaki J, Hinotsu S, Ishizuka N, et al. Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer. Jpn J Clin Oncol. 2013;43(8):827–834. doi:10.1093/jjco/hyt086
   Web of Science ®Google Scholar
• Kamel AI, El Baz AG, Abdel Salam WT, El Din Ryad ME, Mahena AA. Low dose BCG regimen in T1 transitional cell carcinoma of the bladder: long term results. J Egypt Natl Cancer Inst. 2009;21(2):151–155.
   Google Scholar
• Wilson K, Malangone-Monaco E, Satram-Hoang S, et al. A real-world study of patterns of Bacillus Calmette-Guerin (BCG) use and associated adverse events (AEs) in non-muscle invasive bladder cancer (NMIBC) patients in the United States. Ann Oncol. 2016;27(Supplement6):vi355. doi:10.1093/annonc/mdw377.16
   Web of Science ®Google Scholar
• Guerrero-Ramos F, Lara-Isla A, Justo-Quintas J, Duarte-Ojeda JM, de la Rosa-kehrmann F, Villacampa-Auba F. Adjuvant intravesical treatment for nonmuscle invasive bladder cancer: the importance of the strain and maintenance. Actas Urol Esp. 2017;41(9):590–595. doi:10.1016/j.acuro.2017.03.003
   PubMed Web of Science ®Google Scholar
• Takeda T, Kikuchi E, Yuge K, et al. Discontinuance of bacille Calmette-Guerin instillation therapy for nonmuscle-invasive bladder cancer has negative effect on tumor recurrence. Urology. 2009;73(6):1318–1322. doi:10.1016/j.urology.2008.12.039
   Web of Science ®Google Scholar
• Prasanna T, Craft P, Balasingam G, Haxhimolla H, Pranavan G. Intravesical gemcitabine versus intravesical bacillus calmette-guerin for the treatment of non-muscle invasive bladder cancer: an evaluation of efficacy and toxicity. Front Oncol. 2017;7(NOV):260. doi:10.3389/fonc.2017.00260
   Web of Science ®Google Scholar
• Torres J, Travis D, Wong S. Standard of care for non-muscle invasive bladder carcinoma is induction followed by maintenance intra-vesical BCG therapy after trans-urethral bladder tumour resection. But how well is it tolerated? Asia-Pac J Clin Oncol. 2015;11(SUPPL.2):41.
   Google Scholar
• Udovicich C, Nankivell P, Barberi A, et al. Intravesical BCG instillation for non-muscle invasive bladder cancer: prevalence of adverse effects & association with efficacy. BJU Int. 2015;115(SUPPL.4):106–107.
   Google Scholar
• Kanagawa Urological Research Group (KURG). A 2-week maintenance regimen of intravesical instillation of bacillus Calmette-Guerin is safe, adherent and effective in patients with non-muscle-invasive bladder cancer: a prospective, multicenter phase II clinical trial. Jpn J Clin Oncol. 2012;42(9):813–819. doi:10.1093/jjco/hys097
   Web of Science ®Google Scholar
• Nepple KG, Lightfoot AJ, Rosevear HM, O’Donnell MA, Lamm DL. Bladder Cancer Genitourinary Oncology Study Group. Bacillus calmette-guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol. 2010;184(5):1915–1919.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Yuasa T, Sano M, et al. A prospective randomized trial of intravesical bacillus calmette-guerin therapy with the Tokyo172 versus connaught strain for non-muscle invasive bladder cancer. J Urol. 2015;193(4SUPPL. 1):e297. doi:10.1016/j.juro.2015.02.1132
   Web of Science ®Google Scholar
• Parikh A, Tuli A, Laddha P, Singh A, Mammen K. BCG immunotherapy in superficial transitional cell carcinoma of bladder-tertiary care centre experience. Indian J Urol. 2017;33(Supplement1).
   Google Scholar
• Damiano R, De Sio M, Quarto G, et al. Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Guerin-induced toxicity? BJU Int. 2009;104(5):633–639. doi:10.1111/j.1464-410X.2009.08469.x
   Web of Science ®Google Scholar
• Othman B, Steiner D, Wallace S, Travis D. Intravesical BCG for patients with non muscle invasive bladder cancer (NMIBC): do local results reflect those in the published literature. BJU Int. 2013;111(SUPPL.1):115.
   Google Scholar
• Serretta V, Scalici Gesolfo C, Alonge V, Cicero G, Moschini M, Colombo R. Does the compliance to intravesical BCG differ between common clinical practice and international multicentric trials? Urol Int. 2016;96(1):20–24. doi:10.1159/000430501
   PubMed Web of Science ®Google Scholar
• Witjes JA, Palou J, Soloway M, et al. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guerin (BCG): results of an international individual patient data survey (IPDS). BJU Int. 2013;112(6):742–750.
   Web of Science ®Google Scholar
• Chiapparrone G, Gesolfo CS, Solazzo A, et al. Compliance with one year maintenance intravesical BCG in patients affected by t1g3 bladder cancer. Anticancer Res. 2013;33(5):2279–2280.
   Web of Science ®Google Scholar
• Tapiero S, Helfand A, Kedar D, et al. Patient compliance with maintenance intravesical therapy for nonmuscle invasive bladder cancer. Urology. 2018;118:107–113. doi:10.1016/j.urology.2018.04.039
   Web of Science ®Google Scholar
• Lam S, Yang Y, Lo A, Liu M, Ng A, Tsu J. Intravesical bacillus calmette-guerin (IV BCG) treatment for bladder cancer - working toward better patient outcome. Int J Urol. 2017;24(Supplement1):63–64.
   Google Scholar
• Kan RWM, Chung VY, Fan CW. Long-term results of 1-year maintenance intravesical bacille calmette guerin (BCG) therapy with simplified schedule: less is more or less? BJU Int. 2014;113(SUPPL.1):4.
   Google Scholar
• Grant T, Donaldson I, Kadi N, Thomas S, Ratan H. Natural history and outcome of patients with high risk non-muscle invasive bladder cancer treated with Bacille Calmette Guerin: A contemporary UK series. J Urol. 2012;187(4SUPPL. 1):e676. doi:10.1016/j.juro.2012.02.1531
   Web of Science ®Google Scholar
• Babjuk M, Burger M, Comperat E, et al. EAU Guidelines: Non-Muscle-Invasive Bladder Cancer. EAU Guidelines Office; 2017.
   Google Scholar
• Chang SS, Bochner BH, Chou R, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO Guideline. J Urology. 2017;198(3):552–559. doi:10.1016/j.juro.2017.04.086
   PubMed Web of Science ®Google Scholar
• Kubota Y, Nakaigawa N. Committee for establishment of the clinical practice guideline for the management of bladder cancer and the japanese urological association. essential content of evidence-based clinical practice guidelines for bladder cancer: the japanese urological association 2015 update. Int J Urol. 2016;23(8):640–645.
   Web of Science ®Google Scholar
• National Cancer Institute. Definition of cystectomy. Available at: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cystectomy.
   Google Scholar
• Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–128. doi:10.1093/jnci/djq495
   PubMed Web of Science ®Google Scholar
• Mossanen M, Wang Y, Szymaniak J, et al. Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. World J Urol. 2019;37(10):2059–2065.
   PubMed Web of Science ®Google Scholar
• Hollenbeck BK, Ye Z, Dunn RL, Montie JE, Birkmeyer JD. Provider treatment intensity and outcomes for patients with early-stage bladder cancer. J Natl Cancer Inst. 2009;101(8):571–580. doi:10.1093/jnci/djp039
   Google Scholar
• Hollingsworth JM, Zhang Y, Krein SL, Ye Z, Hollenbeck BK. Understanding the variation in treatment intensity among patients with early stage bladder cancer. Cancer. 2010;116(15):3587–3594. doi:10.1002/cncr.25221
   Web of Science ®Google Scholar
• De Jong IJ, Jonker L, Weerink M, Cornel E, Luijendijk D, Leliveld A. The clinical impact of routine bladder biopsy after BCG treatment of high grade non muscle invasive bladder cancer. J Clinical Oncol. 2016;2 SUPPL. 1.
   Google Scholar
• Udell I, Kurpad R, Angela B, et al. The cost impact of routine addition of urovysion FISH early postoperative to non-muscle-invasive bladder cancer surveillance. J Am Coll Surg. 2012;215(3SUPPL. 1):S145–S146.
   Google Scholar
• Vecino-Oritz AI, Glover R, Adams EJ. Modelling the burden of bladder cancer and monitoring cystoscopies in Europe. European Urology Supplements. 2016;15(3):e203. doi:10.1016/S1569-9056(16)60205-1
   Google Scholar
• Dansk V, Malmstrom P-U, Blackberg M, Malmenas M. Hexaminolevulinate hydrochloride blue-light flexible cystoscopy in the detection and follow-up of nonmuscle-invasive bladder cancer: cost consequences during outpatient surveillance in Sweden. Future Oncology. 2016;12(8):1025–1038. doi:10.2217/fon-2015-0021
   PubMed Web of Science ®Google Scholar
• Ihara Z, Furneri G, Haycock L, Chowdhury CA, Besser V. Economic value of narrow band imaging versus white light endoscopy for the management of non-muscle invasive bladder cancer: cost-consequence model. Value Health. 2018;Supplement 3:S253–S254. doi:10.1016/j.jval.2018.09.1514
   Web of Science ®Google Scholar
• Klaassen Z, Li K, Kassouf WW, Black PC, Dragomir A, Kulkarni GS. Contemporary cost-consequences analysis of blue light cystoscopy with hexaminolevulinate in non-muscle invasive bladder cancer (CUA prize winner). Canadian Urological Association J. 2017;6 Supplement 4:S248.
   Google Scholar
• Feifer A, Xie X, Brophy JM, Segal R, Kassouf W. Contemporary cost analysis of single instillation of mitomycin after transurethral resection of bladder tumor in a universal health care system. Urology. 2010;76(3):652–656. doi:10.1016/j.urology.2009.12.070
   Web of Science ®Google Scholar
• Lee CT, Globe D, Colayco D, Gilmore A, Bramley T. Economic consequences of preventable bladder tumor recurrences in non-muscle invasive bladder cancer. Value Health. 2011;3:A179. doi:10.1016/j.jval.2011.02.989
   Web of Science ®Google Scholar
• Al Hussein Al Awamlh B, Lee R, Chughtai B, Donat SM, Sandhu JS, Herr HW. A cost-effectiveness analysis of management of low-risk non-muscle-invasive bladder cancer using office-based fulguration. Urology. 2015;85(2):381–386. doi:10.1016/j.urology.2014.09.041
   Web of Science ®Google Scholar
• Moltke A-L, Drejer D, Jensen JB. Photodynamic diagnosis (PDD) in flexible cystoscopy-impact on effectiveness and costs. A randomized controlled trial. J Urology. 2017;220:37–38.
   Google Scholar
• Garfield SS, Gavaghan MB, Armstrong SO, Jones JS. The cost-effectiveness of blue light cystoscopy in bladder cancer detection: united States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation. J Urology. 2013;20(2):6682–6689.
   Web of Science ®Google Scholar
• Green DA, Rink M, Cha EK, et al. Cost-effective treatment of low-risk carcinoma not invading bladder muscle. BJU Int. 2013;111(3Pt B):E78–84. doi:10.1111/j.1464-410X.2012.11454.x
   Web of Science ®Google Scholar
• Hermann GG, Mogensen K, Rosthoj S. Outpatient diode laser treatment of intermediate-risk non-invasive bladder tumors without sedation: efficacy, safety and economic analysis. Scand J Urol. 2018;52(3):194–198. doi:10.1080/21681805.2018.1450782
   PubMed Web of Science ®Google Scholar
• Jablonowski Z, Konecki T, Ziobro M, et al. Cost-utility of hexaminolevulinate blue light cystoscopy (HAL) assisted transurethral resection of the bladder tumour (TURB) compared to TURB with white light cystoscopy (WLC) alone in patients with non-muscle invasive bladder cancer (NIMBC) in Poland. Value Health. 2015;18(7):A360. doi:10.1016/j.jval.2015.09.694
   Web of Science ®Google Scholar
• James P, Pai A, Chetwood A, et al. Financial benefit of tula (transurethral laser ablation) for recurrent non-muscle invasive bladder cancer. J Endourol. 2017;Supplement 2:A396–A397.
   Google Scholar
• Klaassen Z, Black PC, Kulkarni GS. A cost-effectiveness analysis of hexaminolevulinate blue light-assisted transurethral resection of bladder tumours in a universal healthcare system. Canadian Urological Association J. 2017;11(6Supplement 4):S212–S213.
   Google Scholar
• Malmstrom P-U, Hedelin H, Thomas YK, Thompson GJ, Durrant H, Furniss J. Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden. J Urology. 2009;43(3):192–198.
   Web of Science ®Google Scholar
• Marteau F, Kornowski A, Bennison C, Tempest MJ, Mariappan P, Witjes JA. Cost-effectiveness of the optical imaging agent hexaminolevulina te for patients with non-muscle invasive bladder cancer. Value Health. 2013;16(7):A408–A409. doi:10.1016/j.jval.2013.08.493
   Web of Science ®Google Scholar
• Rose JB, Armstrong S, Hermann GG, Kjellberg J, Malmstrom P-U. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden. BJU Int. 2016;1(6B):E102–113.
   Web of Science ®Google Scholar
• Wong KA, Zisengwe G, Athanasiou T, O’Brien T, Thomas K. Outpatient laser ablation of non-muscle-invasive bladder cancer: is it safe, tolerable and cost-effective? BJU Int. 2013;112(5):561–567. doi:10.1111/bju.12216
   PubMed Web of Science ®Google Scholar
• Bobman J, Deibert C, Ahn J, Stevenson S, Benson M, McKiernan J. Evaluating cost and quality of life in non-muscle invasive bladder cancer. J Urol. 2013;189(4SUPPL. 1):e174. doi:10.1016/j.juro.2013.02.1817
   Web of Science ®Google Scholar
• Lee CT, Barocas D, Globe DR, et al. Economic and humanistic consequences of preventable bladder tumor recurrences in nonmuscle invasive bladder cancer cases. J Urol. 2012;188(6):2114–2119. doi:10.1016/j.juro.2012.08.005
   PubMed Web of Science ®Google Scholar
• de Bekker-grob EW, van der Aa MNM, Zwarthoff EC, et al. Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative? BJU Int. 2009;104(1):41–47. doi:10.1111/j.1464-410X.2008.08323.x
   Web of Science ®Google Scholar
• Fujita N, Momota M, Tobisawa Y, et al. Risk-stratified surveillance and cost effectiveness of follow-up after trans-urethral resection of bladder tumor in patients with primary non-muscle-invasive bladder cancer. European Urology Supplements. 2019;18(1):e951–e952. doi:10.1016/S1569-9056(19)30691-8
   Google Scholar
• Heijnsdijk EAM, Nieboer D, Garg T, Lansdorp-Vogelaar I, de Koning HJ, Nielsen ME. Cost-effectiveness of surveillance schedules in older adults with non-muscle-invasive bladder cancer. BJU Int. 2019;123(2):307–312. doi:10.1111/bju.14502
   PubMed Web of Science ®Google Scholar
• Ok BG, Ji YS, Ko YH, Song PH. Usefulness of urine cytology as a routine work-up in the detection of recurrence in patients with prior non-muscle-invasive bladder cancer: practicality and cost-effectiveness. J Urology. 2014;55(10):650–655.
   Google Scholar
• Bachir BG, Dragomir A, Aprikian AG, et al. Contemporary cost-effectiveness analysis comparing sequential bacillus Calmette-Guerin and electromotive mitomycin versus bacillus Calmette-Guerin alone for patients with high-risk non-muscle-invasive bladder cancer. Cancer. 2014;120(16):2424–2431. doi:10.1002/cncr.28731
   PubMed Web of Science ®Google Scholar
• Bekcic S, Mitrovic L, Baltezarevic D, Radojevic V, Samardzic J, Milenkovic V. Pricing and reimbursement analysis of bacillus calmette-guerin (BCG) immunotherapy for bladder cancer. Value Health. 2014;7:A654.
   Web of Science ®Google Scholar
• Ramamohan V, Mladsi DM, Boey W, Pozzi R, Kaye JA. An outcomes model for high-risk non-muscle-invasive bladder cancer treatment options. Value Health. 2014;3:A87. doi:10.1016/j.jval.2014.03.505
   Web of Science ®Google Scholar
• Ourfali S, Ohannessian R, Fassi-Fehri H, Pages A, Badet L, Colombel M. Recurrence rate and cost consequence of the shortage of bacillus calmette-guerin connaught strain for bladder cancer patients. Eur Urol Focus. 2019. doi:10.1016/j.euf.2019.04.002
   Google Scholar
• Leal J, Luengo-Fernandez R, Sullivan R, Witjes JA. Economic burden of bladder cancer across the European Union. Eur Urol. 2016;69(3):438–447. doi:10.1016/j.eururo.2015.10.024
   PubMed Web of Science ®Google Scholar
• Gerace C, Montorsi F, Tambaro R, et al. Cost of illness of urothelial bladder cancer in Italy. Clinicoecon Outcomes Res. 2017;9:433–442. doi:10.2147/CEOR.S135065
   Web of Science ®Google Scholar
• Avritscher EBC, Cooksley CD, Grossman HB, et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology. 2006;68(3):549–553.
   PubMed Web of Science ®Google Scholar
• Kulkarni GS, Alibhai SMH, Finelli A, et al. Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer. Cancer. 2009;115(23):5450–5459. doi:10.1002/cncr.24634
   Web of Science ®Google Scholar
• Cascone V, Rizza G, Smeriglio A, Tomaino A. Lack of BCG for the treatment of bladder cancer: pharmacoeconomic and clinical impact. Eur J Hosp Pharm. 2014;21(Suppl1):A78.2–A78. doi:10.1136/ejhpharm-2013-000436.192
   Google Scholar
• Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304–314. doi:10.4065/mcp.2010.0575
   PubMed Web of Science ®Google Scholar
• Tsang J, Rudychev I, Pescatore SL. Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM). JCO. 2006;24(18_suppl):6119. doi:10.1200/jco.2006.24.18_suppl.6119
   Web of Science ®Google Scholar
• RAND Healthcare. 36-Item Short Form Survey Instrument (SF-36). Available at: https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form/survey-instrument.html.
   Google Scholar
• Blazeby JM, Hall E, Aaronson NK, et al. Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer. Eur Urol. 2014;66(6):1148–1156. doi:10.1016/j.eururo.2014.02.034
   Web of Science ®Google Scholar
• Danna BJ, Metcalfe MJ, Wood EL, Shah JB. Assessing symptom burden in bladder cancer: an overview of bladder cancer specific health-related quality of life instruments. Bladder Cancer. 2016;2(3):329–340. doi:10.3233/BLC-160057
   Google Scholar
• EORTC. EORTC questionnaires: quality of life of cancer patients. EORTC – Quality of Life.
   Google Scholar
• Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer. Pharmaco Economics. 2003;21(18):1315–1330. doi:10.1007/BF03262330
   PubMed Web of Science ®Google Scholar
• Han KS, Hong SJ. Management of BCG failures in non-muscle-invasive bladder cancer. Korean J Urol. 2009;50(11):1037–1047. doi:10.4111/kju.2009.50.11.1037
   Google Scholar
• Şanlı Ö, Lotan Y. Alternative therapies in patients with non-muscle invasive bladder cancer. Turk J Urol. 2017;43(4):414–424. doi:10.5152/tud.2017.64624
   PubMed Web of Science ®Google Scholar
• de Jong JJ, Hendricksen K, Rosier M, Mostafid H, Boormans JL. Hyperthermic intravesical chemotherapy for BCG unresponsive non-muscle invasive bladder cancer patients. BLC. 2018;4(4):395–401. doi:10.3233/BLC-180191
   Web of Science ®Google Scholar
• Nativ O, Witjes JA, Hendricksen K, et al. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus calmette-guerin. J Urology. 2009;182(4):1313–1317. doi:10.1016/j.juro.2009.06.017
   PubMed Web of Science ®Google Scholar
• Liu K, Zhu J, Song Y-X, et al. Thermal intravesical chemotherapy reduce recurrence rate for non-muscle invasive bladder cancer patients: a meta-analysis. Front Oncol. 2020;10:29. doi:10.3389/fonc.2020.00029
   PubMed Web of Science ®Google Scholar
• Sousa-Escandon MA, Flores Carbajal J, Sousa-Gonzalez D, Rodriguez-Gomez S. Intravesical chemohyperthermia for nmibc: rationale and results of this developing treatment. In: Ather MH, editor. Bladder Cancer - Management of NMI and Muscle-Invasive Cancer. InTech; 2017.
   Google Scholar
• Sousa A, Inman BA, Pineiro I, et al. A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer. Int J Hyperthermia. 2014;30(3):166–170. doi:10.3109/02656736.2014.900194
   PubMed Web of Science ®Google Scholar
• American Urological Association. American Urological Association BCG shortage notice. Available at: https://www.auanet.org/practice-resources/BCG-info/BCG-shortage-notice.
   Google Scholar
• Jung A, Nielsen ME, Crandell JL, et al. Health-related quality of life among non-muscle-invasive bladder cancer survivors: a population-based study. BJU Int. 2020;125(1):38–48. doi:10.1111/bju.14888
   PubMed Web of Science ®Google Scholar
• González-Padilla DA, González-Díaz A, Guerrero-Ramos F, et al. Quality of life and adverse events in patients with nonmuscle invasive bladder cancer receiving adjuvant treatment with BCG, MMC, or chemohyperthermia. Urol Oncol. 2020. doi:10.1016/j.urolonc.2020.07.003
   Web of Science ®Google Scholar
• Sharma V, Wymer KM, Borah BJ, et al. Cost-effectiveness of maintenance bacillus calmette-guérin for intermediate and high risk nonmuscle invasive bladder cancer. J Urol. 2020;204(3):442–449. doi:10.1097/JU.0000000000001023
   Web of Science ®Google Scholar